Toggle Health Problems and D

Hospitalization costs reduced ~3,000 dollars when intravenous nutrition was augmented with Omega-3 – Aug 2019


L Pradelli5 . K. Mayer*. S. Klek\ A. J. Omar Alsaleh1. M. Rosenthal'. A R Heller^. M. Muscaritoli7. 'Adre.s. Torino. Italy: JUmvrnaty Giessen. Giessen Germany: Hanley Dudricks Memorial Hospital Skamna. Poland: 'Via Vittorio Aifieri 17. AdRcs. Torino. Italy. ’’Di vision of Trauma and Acute Care Surgery, University of Florida College of Medicine. Mi am. United States. bAnaesthesiology and Intensive Care Medicine. University of Augsburg. Augsburg, Germany:' Translational and Precision Medicine. Sapienza University of Rome. Rome. Italy

  • Corresponding author.

Vitamin D and Omega-3 category starts with

370 Omega-3 items in category Omega-3 helps with: Autism (9 studies), Depression (28 studies), Cardiovascular (31 studies), Cognition (48 studies), Pregnancy (36 studies), Infant (24 studies), Obesity (12 studies), Mortality (5 studies), Breast Cancer (6 studies), Smoking, Sleep, Stroke, Longevity, Trauma (12 studies), Inflammation (18 studies), Multiple Sclerosis (9 studies), VIRUS (12 studies), etc

   See also - Overview: Omega-3 many benefits include helping vitamin D

See also

"Omega-3 Fatty Acids in Modern Parenteral Nutrition: A Review of the Current Evidence" 2016

Items in both categories Omega-3 and Trauma/Surgery are listed here:

 Download the PDF from VitaminDWiki

Rationale The aim of this study is to perform a cost-consequence analysis of the use of omega-3 (o>-3) fatty-acid enriched parenteral nutrition (PN) in the EUS countries, from the hospital perspective.

Methods: A cost-consequence analysis was performed using a probabilistic discrete event simulation model with country-specific inputs derived from published sources. The relative o>-3 supplementation effect estimates were from our recent meta-analysis 11). The model estimates and compares costs and clinical impact associated with <*-3 fatty-acid enriched PN vs. PN containing standard lipid emulsions (without omega-3 fatty acids; std-PN).
Data captured were

  • cost of PN.
  • cost of infection.
  • cost of hospital length of stay and
  • total cost per patient;
    • clinical events were infections avoided and hospital length of stay.

Inputs uncertainty is evaluated via both deterministic (DSA) and probabilistic (PSA) sensitivity analyses.

Results: Avoided infections and shortened length of stay due to to-3 fatty-acid enriched PN. as compared with std-PN. in the EU5s haw an expected impact on total costs per patient as shown in Table I. Both the PSA and DSA analyses confirmed the robustness of the outputs of the model to all tested changes in the inputs.
Table 1 Reduced costs

UK-2,500 £
Germany -2,200 €
Italy -1,800 €
France -2,200 €
Spain -1,800 €

Conclusion: u>-3 fatty-acid enriched PN is likely a dominant alternative to std-PN from the point of view of a hospital in any of the EUS countries as it is associated with significantly improved patient outcomes and cost savings.

Created by admin. Last Modification: Tuesday August 20, 2019 13:56:42 GMT-0000 by admin. (Version 8)

Attached files

ID Name Comment Uploaded Size Downloads
12510 Omega-3 IV.pdf admin 20 Aug, 2019 13:38 393.37 Kb 318
12509 PN.pdf PDF 2019 admin 20 Aug, 2019 13:32 457.03 Kb 315
See any problem with this page? Report it (WORKS NOV 2021)